NASDAQ:ASND - Ascendis Pharma A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$126.36 +2.20 (+1.77 %)
(As of 05/21/2019 04:00 PM ET)
Previous Close$124.16
Today's Range$125.00 - $127.34
52-Week Range$53.21 - $131.76
Volume212,089 shs
Average Volume356,029 shs
Market Capitalization$5.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.50 million
Book Value$7.87 per share

Profitability

Net Income$-153,650,000.00
Net Margins-1,275.08%

Miscellaneous

Employees216
Market Cap$5.32 billion
Next Earnings Date5/30/2019 (Confirmed)
OptionableOptionable

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its earnings results on Wednesday, April, 3rd. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.17) by $0.30. The biotechnology company had revenue of $12 million for the quarter. Ascendis Pharma A/S had a negative net margin of 1,275.08% and a negative return on equity of 40.86%. View Ascendis Pharma A/S's Earnings History.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Thursday, May 30th 2019. View Earnings Estimates for Ascendis Pharma A/S.

What price target have analysts set for ASND?

9 equities research analysts have issued 12-month price objectives for Ascendis Pharma A/S's shares. Their predictions range from $81.00 to $219.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $135.00 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

What is the consensus analysts' recommendation for Ascendis Pharma A/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

What are Wall Street analysts saying about Ascendis Pharma A/S stock?

Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:
  • 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (3/18/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Ascendis Pharma (ASND) with an Overweight rating and 12-mo. PT of $102. Ascendis is a pro-drug platform company based in Denmark that focuses on endocrinology-based rare diseases. The company leverages its novel pro-drug platform, TransCon™ to improve & extend duration of de-risked clinical-stage drugs’s action in the body. The company has upcoming Ph3 in its lead asset TransCon hGH, for treating growth hormone, expected in 1Q. We remain confident in clinical success of TransCon hGH, which should drive a first leg of upside in 2019. We also think that investors will assign more credit to the platform, especially TransCon PTH with Ph2 data expected YE2019." (1/23/2019)

Has Ascendis Pharma A/S been receiving favorable news coverage?

News articles about ASND stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a news impact score of -1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a decrease in short interest during the month of April. As of April 30th, there was short interest totalling 1,014,539 shares, a decrease of 36.9% from the April 15th total of 1,608,562 shares. Based on an average trading volume of 255,593 shares, the days-to-cover ratio is presently 4.0 days. Currently, 2.4% of the company's stock are short sold. View Ascendis Pharma A/S's Current Options Chain.

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include Neurocrine Biosciences (NBIX), Portola Pharmaceuticals (PTLA), Exelixis (EXEL), Incyte (INCY), AbbVie (ABBV), Abbott Laboratories (ABT), Aimmune Therapeutics (AIMT), Karyopharm Therapeutics (KPTI), Novavax (NVAX) and Sangamo Therapeutics (SGMO).

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (11.14%), Vivo Capital LLC (4.86%), Marshall Wace North America L.P. (2.76%), Artisan Partners Limited Partnership (2.68%), Westfield Capital Management Co. LP (1.63%) and OppenheimerFunds Inc. (1.01%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Vivo Capital LLC, Alps Advisors Inc., Morgan Stanley, BlackRock Inc., California Public Employees Retirement System, Goldman Sachs Group Inc. and Emory University.

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, FMR LLC, Marshall Wace North America L.P., Victory Capital Management Inc., Schonfeld Strategic Advisors LLC, Westfield Capital Management Co. LP, FIL Ltd and Opaleye Management Inc..

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $126.36.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $5.32 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com/.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  230 (Thanks for Voting!)
Underperform Votes:  220 (Thanks for Voting!)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel